Literature DB >> 31592862

Panniculitis-Like Presentation of Extracavitary Primary Effusion Lymphoma.

Andrea Saggini1, Monia Di Prete1, Simone Facchetti1, Vito Mario Rapisarda2, Lucia Anemona1.   

Abstract

Primary effusion lymphoma (PEL) is defined as a HHV-8-associated large B-cell lymphoma, which favors HIV-infected young adults, typically presenting as a serous (pleural, pericardial, or peritoneal) effusion with no identifiable tumor mass. Uncommon instances of lymphoid proliferations with the same morphology, immunophenotype, and molecular features as PEL, but occurring as a solid tumor mass without serous cavities involvement, have been termed extracavitary (or solid) variant of PEL. We hereby report the exceptional case of a HIV-associated extracavitary PEL primarily localized to the skin and exhibiting a panniculitis-like presentation. Primary cutaneous presentation of extracavitary PEL is exceedingly uncommon, with only 6 cases previously described in the literature. In light of its atypical immunophenotype, the differential diagnosis in case of skin involvement by extracavitary PEL is challenging: demonstration of HHV-8 infection in neoplastic cells is of pivotal importance. Our case is further atypical in that the lymphoid proliferation underwent complete and protracted regression solely by establishment of highly active antiretroviral therapy.

Entities:  

Year:  2020        PMID: 31592862     DOI: 10.1097/DAD.0000000000001539

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  2 in total

1.  [Primary effusion lymphoma with multisystemic extracavitary involvement in HIV negative diagnosed by autopsy]

Authors:  Martín Milanesio; Ana Victoria Sánchez; Luciana Guanchiale; Ruth Lía Kaplan
Journal:  Rev Fac Cien Med Univ Nac Cordoba       Date:  2021-12-28

2.  Extracavitary primary effusion lymphoma recurring with syphilis in an HIV-infected patient.

Authors:  Darakhshan Sohail Ahmed; Marc Poliquin; Louis-André Julien; Jean-Pierre Routy
Journal:  BMJ Case Rep       Date:  2020-11-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.